GGrantIndex
← Search

Federated Learning Framework for Multimodal Survival Analysis in Pediatric Cancers

$181,298P30FY2024CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications, trials & patents

Trial NCT07614022Trial NCT07324577Trial NCT07322367Trial NCT07282444Trial NCT07203534Trial NCT07196241Trial NCT07175376Trial NCT07119489Trial NCT07046936Trial NCT06945042Trial NCT06709404Trial NCT06654245Trial NCT06480591Trial NCT06441266Trial NCT06340503Trial NCT05984680Trial NCT05934851Trial NCT05877404Trial NCT05854966Trial NCT05825066Trial NCT05796518Trial NCT05696782Trial NCT05692635Trial NCT05597878Trial NCT05395936Trial NCT05309655Trial NCT05242770Trial NCT05212272Trial NCT05204290Trial NCT05030038Trial NCT04897217Trial NCT04858269Trial NCT04797884Trial NCT04677816Trial NCT04659993Trial NCT04623515Trial NCT04586127Trial NCT04526080Trial NCT04495751Trial NCT04485026Trial NCT04454489Trial NCT04430335Trial NCT04415944Trial NCT04375384Trial NCT04337580Trial NCT04327700Trial NCT04266470Trial NCT04253964Trial NCT04217317Trial NCT04174742Trial NCT04173247Trial NCT04111107Trial NCT04040244Trial NCT04037527Trial NCT03998189Trial NCT03987568Trial NCT03987555Trial NCT03982537Trial NCT03963739Trial NCT03958747Trial NCT03929211Trial NCT03890614Trial NCT03880526Trial NCT03874065Trial NCT03870529Trial NCT03870451Trial NCT03868943Trial NCT03867175Trial NCT03861091Trial NCT03861065Trial NCT03796273Trial NCT03746262Trial NCT03741868Trial NCT03741829Trial NCT03740035Trial NCT03681405Trial NCT03662074Trial NCT03529565Trial NCT03520283Trial NCT03505762Trial NCT03505736Trial NCT03505671Trial NCT03379376Trial NCT03374995Trial NCT03370159Trial NCT03188432Trial NCT03152786Trial NCT03148080Trial NCT03139435Trial NCT03122743Trial NCT03087591Trial NCT03032250Trial NCT02971410Trial NCT02971397Trial NCT02949843Trial NCT02835222Trial NCT02835066Trial NCT02832154Trial NCT02827838Trial NCT02747407

Abstract

Overall Summary/Abstract Childhood cancers, although rare, significantly impact thousands of children globally each year. The complexity and variability of these cancers necessitate extensive research to understand their underlying mechanisms. Given the small number of cases and the diverse genetic and clinical profiles, collaboration across multiple institutions is crucial. The Beat Childhood Cancer (BCC) Research Consortium is a national collaborative group consisting of over 50 institutions and hospitals devoted to research and clinical trials in neuroblastoma, CNS tumors, sarcomas, and other rare solid tumors. Close to 1,000 tumors have been investigated for their genomic and transcriptomic profiles, clinical and imaging data, leading to the establishment of several clinical trials, including the recent FDA approval of DFMO for high-risk neuroblastoma. The BCC cohort is well-positioned to collaborate with other pediatric cancer research consortia and institutes to further the goal of eradicating childhood cancer. Federated learning (FL) offers a novel approach to facilitate such collaborations, allowing researchers to pool data and insights without compromising patient privacy and security. By enabling the analysis of distributed datasets, FL generates robust models and uncovers critical insights, leading to improved diagnostics and therapies for childhood cancers. In this P30 supplement project, we will focus on establishing an FL framework for neuroblastoma and pediatric central nervous system (CNS) tumors. Neuroblastoma is a highly heterogeneous cancer arising from multiple organ sites and primarily affecting young children. Despite advancements in understanding its genomic landscape, the prognosis for high-risk patients remains unfavorable. Pediatric CNS tumors are a diverse group of malignancies that occur in the brain and spinal cord, representing the second most common type of cancer in children. The brain's intricate structure and vital functions make these tumors particularly challenging to treat. The location of the tumor within the brain can greatly influence symptoms and treatment options, impacting critical areas responsible for movement, sensation, cognition, and other essential functions. Pediatric brain tumors encompass a wide range of subtypes, each with distinct biological behaviors and prognoses. Our central hypothesis is that a FL framework can enhance the integration and analysis of diverse pediatric cancer datasets, leading to the identification of multimodal survival predictors and therapeutic targets. We will test this hypothesis through three specific aims: Specific Aim 1: To finalize the implementation of a FL pipeline to securely centralize and analyze diverse datasets from multiple institutions. Specific Aim 2: To elucidate factors that influence survival in pediatric neuroblastoma using machine learning (ML) and FL. Specific Aim 3: To elucidate factors that influence survival in pediatric CNS tumors, including gliomas and medulloblastomas, using ML and FL. This study introduces a novel FL framework for pediatric cancer research, enabling secure, collaborative analysis of diverse datasets. This research promises to advance our understanding of pediatric cancers, improve patient outcomes, and pave the way for AI-driven decision-making applications in healthcare.

View original record on NIH RePORTER →